Skip to main content

Table 3 Relative dose intensity (RDI) for the two treatment regimens

From: Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study

Dose Intensity Rates (DSI) in percentage
GEM Group (n = 9) CIS/GEM Group (n = 21)
   CIS GEM
Cycles Median IQR Cycles Median IQR Median IQR
C1 100 (91.7–100) C1 100 (100–100) 100 (100–100)
C2 100 (95–100) C2 100 (100–100) 100 (100–100)
C3 100 (90.9–100) C3 100 (70–100) 100 (76.4–100)
C4 100 (86.7–100) C4 80 (50–100) 100 (77.5–100)
C5 100 (95–100) C5 80 (50–100) 100 (70–100)
C6 100 (88.9–100) C6 80 (25–100) 94.1 (70–100)
    C7 50 (0–100) 88.9 (56.3–100)
    C8 50 (0–90) 75 (50–100)
Overall DSI 100 (91–100)   100 (50–100) 100 (75–100)
  1. Abbreviations: GEM gemcitabine, CIS cisplatin, IQR interquartile range, C cycles